X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.980
-0.020 (-0.50%)
At close: Jul 31, 2026, 4:00 PM EDT
3.970
-0.010 (-0.25%)
After-hours: Jul 31, 2026, 7:34 PM EDT

X4 Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
9.0135.112.56---
Revenue Growth
-71.26%1273.21%-14.77%---
Cost of Revenue
1.645.760.8---
Gross Profit
7.3829.361.76---
Selling, General & Admin
35.4643.5261.5235.5127.0224.7
Research & Development
69.6672.7281.6472.0261.0650.65
Other Operating Expenses
--105-0.519.76
Total Operating Expenses
105.12116.24248.16107.5288.5985.11
Operating Income
-97.75-86.88-246.4-107.52-88.59-85.11
Interest Income
5.664.585.774.580.220.01
Interest Expense
-8.81-8.88-8.77-5.78-3.99-3.64
Other Non-Operating Income (Expense)
1.1812.032.267.63-2.50.06
Total Non-Operating Income (Expense)
-1.977.73-0.746.43-6.27-3.57
Pretax Income
-99.72-79.16-37.14-101.09-93.84-88.68
Provision for Income Taxes
0.010.040.310.080.030.02
Net Income
-99.72-79.2-37.45-101.17-93.87-88.7
Net Income Attributable to Preferred Dividends
----2.5513.94
Net Income to Common
-99.72-79.2-37.45-101.17-91.32-74.75
Net Income Growth
------
Shares Outstanding (Basic)
72427621
Shares Outstanding (Diluted)
72427621
Shares Change
967.33%531.04%13.08%179.91%146.71%28.25%
EPS (Basic)
-3.32-1.87-5.59-17.07-45.60-119.70
EPS (Diluted)
-3.32-1.87-5.59-17.07-45.60-119.70
EPS Growth
------
Free Cash Flow
-92.85-85.62-131.23-96.57-77.21-71.52
Free Cash Flow Growth
------
Free Cash Flow Per Share
-1.29-2.02-19.58-16.29-36.46-83.33
Gross Margin
81.82%83.60%68.83%---
Operating Margin
-1084.38%-247.44%-9636.33%---
Profit Margin
-1106.30%-225.56%-1464.61%---
FCF Margin
-1030.05%-243.84%-5132.07%---
EBITDA
-96.72-85.61-245.61-107.1-88.07-84.61
EBITDA Margin
-1073.02%-243.80%-9605.20%---
EBIT
-97.75-86.88-246.4-107.52-88.59-85.11
EBIT Margin
-1084.38%-247.44%-9636.33%---
Effective Tax Rate
-0.01%-0.05%-0.83%-0.08%-0.03%-0.02%
SEC Filings: 10-K · 10-Q